用乙基和基酸盐调节炎症和cuproptotic交叉:对实验性结肠炎的多目标策略
Priyanka Raju Chougule1,2,3, Sukesh Narayan Sinha4, Sudip Ghosh2
1Food Safety Division, Indian Council of Medical Research - National Institute of Nutrition, Jamai-Osmania, 500007, Hyderabad, India.
Molecular biology reports
|October 14, 2025
概括
乙基酸 (EG) 和基酸 (PG) 通过减少炎症,氧化应激和亡来保护大肠炎. 这项研究揭示了它们在缓解cuproptosis中的新作用,为性结肠炎提供了以食物为基础的治疗方法的潜力.
科学领域:
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
- 营养科学 营养科学
背景情况:
- 性结肠炎 (UC) 涉及氧化应激,免疫问题和屏障功能障碍.
- 现有的UC治疗方法存在局限性.
- 来自食物的抗氧化剂提供了一个有前途的治疗途径.
研究的目的:
- 研究乙基酸 (EG) 和基酸 (PG) 对小鼠中硫酸 (DSS) 诱导的大肠炎的保护作用.
- 阐明EG和PG对炎症,氧化应激,亡和亡的影响.
主要方法:
- 在小鼠中使用DSS诱导大肠炎.
- 小鼠接受了EG,PG或其组合的治疗.
- 通过使用ELISA,qPCR,西部涂抹和TUNEL测定分析了关键的分子通路 (NF-κB,JAK-STAT,Nrf2/HO-1,细胞亡,cuproptosis).
主要成果:
- 通过抑制NF-κB和JAK-STAT通路,EG和PG显著降低了促炎性细胞因子 (TNF-α,IL-1β,IL-6).
- 它们激活了Nrf2/HO-1通路,减轻了氧化应激.
- 抑制了亡,并保持了肠道屏障的完整性.
- 通过降低FDX1,DLAT和LIAS的调节,EG和PG减轻了cuproptosis.
结论:
- 含有富含铜水的EG和PG在DSS诱导的大肠炎中显示出显著的保护作用.
- 这项研究是首次表明EG和PG调节与cuproptosis相关的蛋白质.
- 这些发现支持EG和PG作为潜在的基于食物的治疗肠道疾病的药物.
更多相关视频
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
456
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
456
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
488
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
488
Inflammatory Bowel Disease IV: Pharmacological Management
517
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
517
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
490
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
490
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
434
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
434
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.1K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.1K


